Syndrome News and Research

RSS

Human antibody response to SARS-CoV-2

A new study published on the preprint server medRxiv* in August 2020 reports on the human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is key to developing vaccines and managing the pandemic, as well as designing and executing serologic testing and interpreting their results.

1 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

Study: Impact of COVID-19 virus goes far beyond the pulmonary system

Described as a novel, "once-in-a-century" disease, COVID-19 research is evolving to include a growing body of evidence that the virus's impact goes far beyond the pulmonary system.

1 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Scientists explain why SARS-CoV-2 targets multiple organs

Now, a team of researchers at LSU Health New Orleans’ Neuroscience Center of Excellence and School of Medicine has explained the gateway receptor for SARS-CoV-2 and how it leads to the emergence of many complications as it targets many parts of the body.

31 Aug 2020

Majority of U.S. COVID-19 fatalities had underlying medical conditions

Early on in the coronavirus disease (COVID-19) pandemic, there was little data on the virus and how it affects the body. As the virus spread across the globe, data showed that some people were at a higher risk of developing severe disease and dying from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

31 Aug 2020

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

A research group from Slovenia, Switzerland, and Germany shows how nanoscaffolded assemblies may neutralize interaction between the SARS-CoV-2 spike protein and cell receptor, providing adequate protection in a surrogate infection assay and warranting the advance of such platforms in the pursuit for the effective vaccine.

31 Aug 2020

Scientists solve structure of ORF8 coronavirus protein

Researchers at the University of California and the Lawrence Berkeley National Laboratory have made important discoveries about a protein found on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could lay the foundations for the development of new treatments.

31 Aug 2020

COVID-19 patients may experience long-term cardiovascular complications

Researchers at the University of Washington in Seattle have conducted a study suggesting that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect heart tissue and contribute to whole-organ cardiac dysfunction.

31 Aug 2020

Study identifies effective treatment for severe COVID-19 patients

As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.

31 Aug 2020

Older adults living in disadvantaged neighborhoods more likely to experience post-op delirium

Where you live can increase your risk for experiencing delirium after surgery. So said a study that showed older adults who live in the most disadvantaged neighborhoods are two times more likely to experience delirium after surgery than their counterparts from more affluent communities.

31 Aug 2020

T cell epitopes from recovered COVID-19 patients identified for vaccine

A new study by researchers at The Hong Kong University of Science and Technology and published on the preprint server bioRxiv in August 2020 collates the available database of SARS-CoV-2 T cell epitopes gathered from 8 studies of COVID-19 patients who recovered. This could serve as a launchpad to fill in knowledge gaps regarding the immunological aspects of this disease, and drive towards an effective T cell vaccine.

31 Aug 2020

Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy

Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to results of the EAST-AFNET 4 trial presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

IL-6 signaling blockade can alleviate severe COVID-19

A team of researchers led by Osaka University find an overlap in the pathogenesis of cytokine release syndrome and COVID-19, and show that the symptoms of both can be alleviated by IL-6 signaling blockade

31 Aug 2020

ESC publishes treatment guidelines for non-ST-segment elevation acute coronary syndrome

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

31 Aug 2020

Cat antiviral that inhibits SARS-CoV-2 fast-tracked for human clinical trials

Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.

31 Aug 2020

Serum protein shows therapeutic value against severe COVID-19-like features in mouse model

A new study published on the preprint server bioRxiv* in August 2020 reports the disease-mitigating effects of a serum protein called serum amyloid P (SAP) in mice exposed to a peptide that mimics the clinical signs of severe COVID-19 in humans.

30 Aug 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

Using SARS-CoV-2 epitope to construct a vaccine

A new study published on the preprint server bioRxiv* in August 2020 reports the use of prediction and advanced simulation techniques to identify a novel T cell epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as the basis for a customized vaccine with broad-based efficacy.

30 Aug 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020